Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
“We’re not just going to rubber-stamp new products that don’t work, that fail in a clinical trial,” he said.
Simplified Text
He said We’re not going to rubber-stamp new products that don’t work that fail in a clinical trial
Confidence Score
0.950
Claim Maker
Dr. Makary
Context Type
News Article
Context Details
{
    "person_speaking": "Dr. Makary",
    "statement_context": "approving new products"
}
UUID
a1164c06-626b-4116-ae3c-f794dafed745
Vector Index
✗ No vector
Created
February 15, 2026 at 4:02 PM (7 months ago)
Last Updated
February 15, 2026 at 4:02 PM (7 months ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html
F.D.A. Rejects Moderna’s M.R.N.A. Flu Vaccine, a Sign of Policy Shift
Completed News
30 claims 🔥
1 month ago
https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html

The FDA rejected Moderna's mRNA flu vaccine, signaling a shift in federal health policy under Health Secretary Robert F. Kennedy Jr. The rejection is based on concerns about the clinical trial's comparison product. Moderna's stock has plummeted since its peak.

FDA Moderna mRNA Vaccine Flu Vaccine Robert F. Kennedy Jr. Vaccine Policy Vaccine Development

Similar Claims (5)

Other claims identified as semantically similar to this one.